Logo

Aclaris Therapeutics, Inc.

ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Con… read more

Healthcare

Diagnostics & Research

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$5.53

Price

+6.35%

$0.33

Market Cap

$772.340m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-988.1%

EBITDA Margin

-993.2%

Net Profit Margin

-909.3%

Free Cash Flow Margin

-988.1%

EBITDA Margin

-993.2%

Net Profit Margin

-909.3%

Free Cash Flow Margin
Revenue

$8.367m

+6.9%

1y CAGR

-30.5%

3y CAGR

-21.6%

5y CAGR
Earnings

-$69.662m

-7.3%

1y CAGR

-1.9%

3y CAGR

-1.9%

5y CAGR
EPS

-$0.56

-5.7%

1y CAGR

+9.6%

3y CAGR

+8.3%

5y CAGR
Book Value

$143.649m

$198.720m

Assets

$55.071m

Liabilities

$1.985m

Debt
Debt to Assets

1.0%

-

Debt to EBITDA
Free Cash Flow

-$52.273m

-10.9%

1y CAGR

-23.2%

3y CAGR

-21.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases